Advertisement

Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet’s disease

  • Leyla Suna Atmaca
  • F. Nilüfer Yalçindağ
  • Özden Özdemir
Clinical Investigation

Abstract

Purpose

To determine the efficacy of intravitreal triamcinolone acetonide (ivTA) injection in the management of cystoid macular edema (CME) due to uveitis in patients with Behçet’s disease.

Methods

Ten eyes of seven patients with CME associated with Behçet’s disease were included in the study. A quantity of 4 mg of triamcinolone acetonide was injected intravitreally in all of the eyes. The maculas of the patients were evaluated with optical coherence tomography (OCT) and fluorescein angiography (FA). The change in visual acuity, fluorescein leakage, macular thickness, and potential complications were assessed.

Results

The mean follow-up was 15.6 months (range 7–19 months). There was an increase of more than two Snellen lines in the visual acuity in seven of the ten eyes (70%) at the last examination. Macular edema regressed completely in eight of the ten eyes (80%) at the last visit on OCT and FA. The mean central macular thickness assessed by OCT was 406 μm before treatment and 186.9 μm at the last visit. The intraocular pressure (IOP) exceeded 21 mmHg in six eyes of five patients (60%) during the follow-up. At the last visit, the IOP was less than 21 mmHg in five eyes with medication. One eye underwent glaucoma filtration surgery. Four eyes of three patients had cataract progression. In four eyes of four patients (40%), a second ivTA injection was given due to relapsing CME.

Conclusion

Intravitreal triamcinolone acetonide (ivTA) may be beneficial in the management of CME in patients with Behçet’s disease. Repeated ivTA injections might be required if CME reoccurs.

Keywords

Behçet’s disease Cataract Cystoid macular edema Intraocular pressure Intravitreal injection Triamcinolone acetonide 

References

  1. 1.
    Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster CS (2005) Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm 13(2–3):205–212PubMedCrossRefGoogle Scholar
  2. 2.
    Anticliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108(4):765–772CrossRefGoogle Scholar
  3. 3.
    Bakri SJ, Beer PM (2003) The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 34(5):386–390PubMedGoogle Scholar
  4. 4.
    Behçet H (1937) Uber rezidivirende Aphthose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105:1152–1157Google Scholar
  5. 5.
    BenEzra D (1999) Behçet’s disease. In: BenEzra D (ed) Ocular inflammation. Basic and clinical concepts. Martin Dunitz, London, UK, pp 324–325Google Scholar
  6. 6.
    International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335(8697):1078–1080Google Scholar
  7. 7.
    Jonas JB, Kreissig I, Degenring RF (2003) Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 87(1):24–27PubMedCrossRefGoogle Scholar
  8. 8.
    Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA (2005) Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmol 112(4):593–598Google Scholar
  9. 9.
    Karaçorlu M, Mudun B, Ozdemir H, Karacorlu SA, Burumcek E (2004) Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease. Am J Ophthalmol 138(2):289–291PubMedCrossRefGoogle Scholar
  10. 10.
    Kok H, Lau C, Maycock H, McCluskey P, Lightman S (2005) Outcome of intravitreal triamcinolone in uveitis. Ophthalmol 112(11):1916–1921Google Scholar
  11. 11.
    Martidis A, Duker JS, Puliafito CA (2001) Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 119(9):1380–1383PubMedGoogle Scholar
  12. 12.
    Mishima H, Masuda K, Miyake K (1989) The putative role of prostaglandins in cystoid macular edema. Prog Clin Biol Res 312:251–264PubMedGoogle Scholar
  13. 13.
    Okhravi N, Lightman S (2003) Cystoid macular edema in uveitis. Ocul Immunol Inflamm 11(1):29–38PubMedCrossRefGoogle Scholar
  14. 14.
    Özkiriş A, Erkiliç K (2005) Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 40(1):63–68PubMedGoogle Scholar
  15. 15.
    Reichie ML (2005) Complications of intravitreal steroid injections. Optometry 76(8):450–460Google Scholar
  16. 16.
    Rizzi R, Bruno S, Dammacco R (1997) Behçet’s disease: an immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 27(4):225–232PubMedCrossRefGoogle Scholar
  17. 17.
    Rothova A (2002) Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 10(4):239–246PubMedCrossRefGoogle Scholar
  18. 18.
    Wingate RJB, Beaumont PE (1999) Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 27(6):431–432PubMedCrossRefGoogle Scholar
  19. 19.
    Yazıcı H, Tüzün Y, Pazarlı H, Yurdakul S, Ozyazgan Y, Ozdogan H, Serdaroglu S, Ersanli M, Ulku BY, Muftuoglu AU (1984) Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis 43(6):783–789PubMedCrossRefGoogle Scholar
  20. 20.
    Young S, Larkin G, Branley M, Lightman S (2001) Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 29(1):2–6PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Leyla Suna Atmaca
    • 1
    • 2
  • F. Nilüfer Yalçindağ
    • 1
  • Özden Özdemir
    • 1
  1. 1.Department of OphthalmologyAnkara University Medical SchoolAnkaraTurkey
  2. 2.AnkaraTurkey

Personalised recommendations